[1] |
Institute for Health Metrics and Evaluation. Country Profile-Nigeria [DS/OL]. [2022-04-23]. http://www.healthdata.org/nigeria.
|
[2] |
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1204-1222. doi:10.1016/S0140-6736(20)30925-9.
|
[3] |
Adepoju P. AGHI: helping gay men in Nigeria. Lancet HIV, 2020, 7(11): e738. doi:10.1016/S2352-3018(20)30276-9.
|
[4] |
Odume B, Meribe SC, Odusote T, et al. Taking tuberculosis preventive therapy implementation to national scale: the Nigerian PEPFAR Program experience. Public Health Action, 2020, 10(1): 7-10. doi:10.5588/pha.19.0033.
|
[5] |
World Health Organization. Tuberculosis country profiles, TB burden estimates and country-reported TB data, Nigeria. Geneva: World Health Organization, 2018.
|
[6] |
World Health Organization. TB/HIV/HIV-associated TB facts 2013. Geneva: World Health Organization, 2013.
|
[7] |
Federal Ministry of Health, Department of Public Health. First national TB prevalence survey 2012, Nigeria[R/OL]. [2021-12-01]. https://www.who.int/tb/publications/NigeriaReport_WEB_NEW.pdf.
|
[8] |
Federal Ministry of Health, Department of Public Health.The National Strategic Plan for Tuberculosis Control: Towards Universal Access to Prevention, Diagnosis and Treatment (2015-2020) [R/OL]. [2021-12-01]. https://health.gov.ng/doc/National Strategic Plan for Tuberculosis Control 2015_2020.pdf.
|
[9] |
The Joint United Nations Programme on HIV/AIDS. New survey results indicate that Nigeria has an HIV prevalence of 1.4%[R/OL]. [2021-12-01]. https://reliefweb.int/sites/reliefweb.int/files/resources/20190314_PR_Nigeria_en.pdf.
|
[10] |
Oga-Omenka C, Zarowsky C, Agbaje A, et al. Rates and timeliness of treatment initiation among drug-resistant tuberculosis patients in Nigeria-A retrospective cohort study. PLoS One, 2019, 14(4): e0215542. doi:10.1371/journal.pone.0215542.
|
[11] |
Oga-Omenka C, Tseja-Akinrin A, Sen P, et al. Factors influen-cing diagnosis and treatment initiation for multidrug-resistant/rifampicin-resistant tuberculosis in six sub-Saharan African countries: a mixed-methods systematic review. BMJ Glob Health, 2020, 5(7): e002280. doi:10.1136/bmjgh-2019-002280.
|
[12] |
Lawson L, Yassin MA, Ramsay A, et al. Comparison of scanty AFB smears against culture in an area with high HIV prevalence. Int J Tuberc Lung Dis, 2005, 9(8): 933-935.
|
[13] |
吴桂辉, 黄涛. TB/HIV双重感染者治疗中的问题与建议. 结核与肺部疾病杂志, 2020, 1(1): 11-16. doi:10.3969/j.issn.2096-8493.2020.01.004.
|
[14] |
Boyd AT, Odume B, Sidibe K, et al. Brief Report: Programmatic Scale-up of Tuberculosis Preventive Treatment Among People Living With HIV Through Targeted Technical Assistance to High-Volume Antiretroviral Treatment Sites-Nigeria, 2018-2019. J Acquir Immune Defic Syndr, 2020, 85(4): 450-453. doi:10.1097/QAI.0000000000002483.
|
[15] |
Abdullahi SA, Smelyanskaya M, John S, et al. Providing TB and HIV outreach services to internally displaced populations in Northeast Nigeria: Results of a controlled intervention study. PLoS Med, 2020, 17(9): e1003218. doi:10.1371/journal.pmed.1003218.
|